QCM
PTGX icon

Quantinno Capital Management’s Protagonist Therapeutics PTGX Stock Holding History

Quantinno Capital Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1M Buy
8,176
+1,739
+27% +$182K ﹤0.01% 2560
2026
Q1 		$678K Buy
6,437
+1,489
+30% +$132K ﹤0.01% 2485
2025
Q4 		$432K Buy
4,948
+901
+22% +$73.7K ﹤0.01% 2560
2025
Q3 		$269K Buy
+4,047
New +$230K ﹤0.01% 2547

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Quantinno Capital Management's PTGX Position: Q2 2026 in Review

Quantinno Capital Management increased its Protagonist Therapeutics (PTGX) stake by 27% in Q2 2026, buying an estimated $182K and bringing the position to 8,176 shares worth $1M. The position accounts for ﹤0.01% of the portfolio, ranked #2560.

Quantinno Capital Management first reported a position in PTGX in Q3 2025 and has held it in 4 quarters since. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Quantinno Capital Management held 8,176 shares of Protagonist Therapeutics worth $1M as of Q2 2026.
  • Quantinno Capital Management bought 1,739 Protagonist Therapeutics shares in Q2 2026, an estimated $182K.
  • Protagonist Therapeutics made up ﹤0.01% of Quantinno Capital Management's portfolio in Q2 2026, its #2560 holding.
  • Quantinno Capital Management first reported a position in Protagonist Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Quantinno Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.